These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 19601707

  • 1. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, Chandrasena R, Thakur A, Dickson R.
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [Abstract] [Full Text] [Related]

  • 2. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S, Agoston T, Tamás T, Zoltán J.
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [Abstract] [Full Text] [Related]

  • 3. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [Abstract] [Full Text] [Related]

  • 4. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [Abstract] [Full Text] [Related]

  • 5. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B, Mellino G, Pintore S, Puddu L, Pinna F.
    Clin Ter; 2011 Dec; 162(4):331-41. PubMed ID: 21912821
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I, IC-SOHO Study Group.
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [Abstract] [Full Text] [Related]

  • 7. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
    Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J.
    BMC Psychiatry; 2005 May 27; 5():26. PubMed ID: 15921508
    [Abstract] [Full Text] [Related]

  • 8. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ, Nakonezny PA, Bettcher BM, Carmody T, Fisher R, Rush AJ.
    Schizophr Res; 2006 Sep 27; 86(1-3):244-50. PubMed ID: 16730951
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H.
    Hum Psychopharmacol; 2008 Aug 27; 23(6):455-63. PubMed ID: 18537222
    [Abstract] [Full Text] [Related]

  • 10. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S.
    Schizophr Res; 2010 Nov 27; 123(2-3):225-33. PubMed ID: 20692814
    [Abstract] [Full Text] [Related]

  • 11. Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.
    Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM.
    J Nerv Ment Dis; 2012 Jul 27; 200(7):637-43. PubMed ID: 22759944
    [Abstract] [Full Text] [Related]

  • 12. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.
    Cohen D.
    Pharmacopsychiatry; 2004 Jan 27; 37(1):1-11. PubMed ID: 14750042
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I, Czobor P, Dossenbach M, Volavka J.
    Eur Psychiatry; 2005 Aug 27; 20(5-6):403-8. PubMed ID: 16084068
    [Abstract] [Full Text] [Related]

  • 14. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.
    J Am Pharm Assoc (2003); 2007 Aug 27; 47(3):373-8. PubMed ID: 17510032
    [Abstract] [Full Text] [Related]

  • 15. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E, Valsecchi P, Parrinello G, QUERISOLA Group.
    Schizophr Res; 2008 Jan 27; 98(1-3):55-65. PubMed ID: 17933497
    [Abstract] [Full Text] [Related]

  • 16. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM, Novick D, Suarez D, Roca M.
    J Psychiatr Res; 2009 Jan 27; 43(3):265-73. PubMed ID: 18644606
    [Abstract] [Full Text] [Related]

  • 17. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
    Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, Naber D.
    Acta Psychiatr Scand; 2005 Mar 27; 111(3):232-43. PubMed ID: 15701108
    [Abstract] [Full Text] [Related]

  • 18. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.
    Pharmacoepidemiol Drug Saf; 2005 Jun 27; 14(6):417-25. PubMed ID: 15786516
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK, CATIE Investigators.
    Am J Psychiatry; 2007 Mar 27; 164(3):415-27. PubMed ID: 17329466
    [Abstract] [Full Text] [Related]

  • 20. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C.
    Bipolar Disord; 2010 Mar 27; 12(2):172-84. PubMed ID: 20402710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.